The Open Translational Medicine Journal




(Discontinued)

ISSN: 1876-3995 ― Volume 3, 2014

Differential Effects of Recombinant Human EGF on Proliferation and Radiation Survival of Normal Fibroblast and Cancer Cell Lines



Eun-Kyung Kwon1, 2, 4, Seung-Hee Lee1, Kyubo Kim1, Hong-Gyun Wu* , 1, 4, Sang-wook Lee5
1 Department of Radiation Oncology, Seoul National University College of Medicine, Seoul, Republic of Korea
2 Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea
3 Institute of Radiation Medicine, Medical Research Center, Seoul National University, Seoul, Republic of Korea
4 Radiation Applied Life Science Interdisciplinary Course, Seoul National University Graduate School, Seoul, Republic of Korea
5 Department of Radiation Oncology, University of Ulsan, College of Medicine, Asan Medical Center, Seoul, Republic of Korea

Abstract

Objective:

To evaluate the effects of recombinant human epidermal growth factor (rhEGF) on proliferation and radiation survival of normal fibroblast and cancer cell lines both in vitro and in vivo.

Methods:

Using normal fibroblast and cancer cell lines, we evaluated the expression of EGFR, and determined their proli-feration and survival with rhEGF alone or in combination with radiation. For the combination treatments, we applied 10 nM rhEGF and delivered single radiation doses of 0, 2, 5, and 10 Gy. In the animal study, we introduced EMT-6 cells into BALB/c mice to assay for tumor growth delay. We applied single radiation dose of 10 or 20 Gy, with or without 1.0 mg/Kg of rhEGF, three times a day, for 7 days.

Results:

In a dose-dependent manner, rhEGF stimulated proliferation of the normal fibroblast, but not the cancer cell lines with low or intermediate expression of EGFR. rhEGF inhibited proliferation of the cancer cell line with the highest EGFR expression. Administration of rhEGF in combination with radiation attenuated the cell killing effect of radiation in normal fibroblast, but it had no effect or even augmented the radiation effect in cancer cell lines. In the animal study, we observed no difference in tumor growth rates when rhEGF was combined with radiation compared to radiation alone.

Conclusions:

Our results suggested that rhEGF might be useful in preventing and/or treating radiation-induced injury without stimulating tumor growth.

Mini-Abstract:

rhEGF effectively stimulated proliferation and radiation recovery in normal fibroblasts without promoting the growth of tumor cells. Therefore, it might be useful in preventing and/or treating radiation-induced tissue injury.

Presented at the 49th Annual Meeting of the American Society for Therapeutic Radiology and Oncology, Oct 28-Nov 1, 2007, Los Angeles, CA.

Keywords: Recombinant human epidermal growth factor, radiotherapy, in vitro study, in vivo study.


Article Information


Identifiers and Pagination:

Year: 2009
Volume: 1
First Page: 9
Last Page: 15
Publisher Id: TOTRANSMJ-1-9
DOI: 10.2174/1876399500901010009

Article History:

Received Date: 30/4/2009
Revision Received Date: 11/1/2009
Acceptance Date: 11/6/2009
Electronic publication date: 5 /11/2009
Collection year: 2009

© Kwon et al.; Licensee Bentham Open.

open-access license: This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.


* Address correspondence to this author at the Department of Radiation Oncology, Seoul National University College of Medicine, 101 Daehangno, Jongno-gu, Seoul 110-774, Republic of Korea; Tel: +82-2-2072-3177; Fax: +82-2-765-3317; E-mail: wuhg@snu.ac.kr





INTRODUCTION

Radiation-induced mucosal injury is a common side-effect observed during and after local irradiation of the head and neck and gastrointestinal tract, and it can mediate dose-limiting toxicity that hinders treatment progress. Until recently, no specific method was available to prevent or treat radiation-induced injuries. Besides conservative and/or supportive management for these injuries, the recovery of radiation-induced tissue injury with growth factors or cytokines is under investigation [1-8].

The US Food and Drug Administration has recently approved Palifermin, a recombinant human keratinocyte growth factor [8], for preventing severe oral mucositis in hematologic malignancy patients receiving myelotoxic therapies and hematopoietic stem cell transplantation. Application of Palifermin for radiation-induced oral mucositis in solid tumors has not been approved yet, although clinical trials are under way. Recently, two animal models were developed for the elucidation of the role of epidermal growth factor (EGF) in the treatment of radiation-induced oral and gastrointestinal mucositis, and recombinant human EGF (rhEGF) was shown to be effective for the recovery of radiation-induced mucosal damage [9,10].

EGF, which is produced by platelets, macrophages, and monocytes, interacts with EGFR on epidermal cells and fibroblasts [11]. Besides stimulating epithelial proliferation, EGF induces a variety of responses, including modification of migration and differentiation processes within epithelial cells [12-14]. EGF also plays a major role in stimulating fibroblasts during the early phases of wound healing [15,16]. Several other studies have reported that EGF and other growth factors exerted beneficial effects in normal fibroblasts [11,17,18]. However, little is known about the effect of EGF on the proliferation of tumor cells and on the survival of irradiated tumor cells. Since EGF and EGFR play an important role in the development and growth of some tumors [16], we designed this study to evaluate the effect of rhEGF on proliferation and radiation survival of cancer cell lines and normal fibroblasts, both in vitro and in vivo.

MATERIALS AND METHODOLOGY

1. Study Drug

rhEGF used in this study was provided by Daewoong Parmaceutical Co. Ltd. (Seoul, Korea). This product is commercially available and indicated for diabetic foot in Korea.

2. Cell Lines

To compare expression level of EGF receptor (EGFR), various cancer cell lines were used. NCI-H460, NCI-H1299, A549 (human lung carcinoma), HeLa (human cervical adenocarcinoma), and EMT-6 (mouse mammary sarcoma) were purchased from the American Type Culture Collection (ATCC). AMC-HN9 and AMC-HN3 (human head and neck cancer cell lines) were generous gifts from Prof. Sang-wook Lee at University of Ulsan, Seoul, Korea. Normal primary human cervix fibroblasts and F65 human skin fibroblasts were also used, and these were kind gifts from Prof. Yong-Sang Song at Seoul National University, Seoul, Korea and Prof. Joon Kim at Korea University, Seoul, Korea, respectively.

Cells were maintained at 37 °C and 5% CO2 and cultured in RPMI 1640 (Gibco BRL; Gaithersburg, MD, USA), DMEM (Gibco BRL; 31600 034, Grand Island, NY, USA), or MEM (Gibco BRL). All media were supplemented with 10-20% FBS (Sigma; St. Louis, MO, USA). Serum-free media (0.05% FBS) were also used in order to exclude the effects of other growth factors in the FBS.

3. Clonogenic Assay: rhEGF Alone

Mid-log phase cells from monolayer cultures were trypsinized and plated in six-well culture plates at cell densities that were optimized for the experimental conditions indicated: 2 x 102 cells were plated for AMC-HN3 cells, and 1 x 102 cells for other cell lines according to treatment conditions. The cells were then incubated for 24 hours prior to treatment. To measure the effect of rhEGF, 0, 0.01, 0.1, 1, 10, 100, and 1000 nM rhEGF were added to the medium. Cells were incubated for additional 10 days at 37 °C without changing the medium, resulting in the formation of colonies. The cells were then fixed with 100% methanol and stained with 0.5% crystal violet in methanol. The numbers of colonies (defined as more than 50 cells) were counted. Surviving fraction (SF) was defined as the ratio of the numbers of colonies to the numbers of initially plated cells corrected by plating efficiency (PE), where PE was SF of untreated cells. Each experiment was independently repeated three times.

4. Clonogenic Assay: Combination of rhEGF and Radiation

In the experiments using radiation with or without rhEGF, 1 x 102 cells were plated for dose of 2 Gy, 3 x 102 cells for 5 Gy, and 1 x 103 cells for 10 Gy, for all cell lines. The cells were then incubated for 24 hours prior to treatment. To compare the combined effect of rhEGF and radiation with the effect of radiation alone, cells were irradiated with 4 MV X-rays generated by a linear accelerator (Clinac 4/100; Varian; Palo Alto, CA), at a dose rate of 2.46 Gy/min. Where indicated, rhEGF was added to the media at the concentration of 10 nM for 24 hours, after which cells were irradiated in the presence of rhEGF. After 24 hours, the medium was removed, and cells were incubated in drug-free media for 10 days to form colonies. Each experiment was independently repeated three times.

5. Western Blot Analysis

Cells were harvested using cold lysis buffer (iNtRON Biotechnology; Seoul, Korea). The lysates were sonicated, clarified by centrifugation at 13,000 rpm for 20 minutes at 4 °C, and the supernatants were utilized for analysis. Protein concentrations of the samples were determined with a BCA protein assay kit (PIERCE; Rockford, IL, USA.). The protein was mixed with 5X sample buffer (2% SDS, 5% β-mercaptoethanol, 20% glycerol, 0.001% bromophenol-blue, 0.1 M Tris-HCl, pH 6.8) and boiled for 10 minutes. Equal amounts of protein were separated by 6-8% SDS-PAGE and transferred to PVDF membranes (Millipore Corp; Bedford, MA, USA). Membranes were blocked for 1 hour at room temperature with TBST (10 nM Tris-HCl [pH 7.5], 150 mM NaCl, 0.1% Tween 20) containing 5% dry milk, and then washed three times with TBST. Membranes were probed at 4 °C overnight with polyclonal rabbit anti-EGFR (Cell Signaling Technology; Beverly, MA, USA), polyclonal rabbit anti-PCNA (Sigma), polyclonal rabbit anti-Ki67 (abcam®; Cambridge, UK), at respective dilutions of 1:500, 1:10000, and 1:250. The blots were then incubated with peroxidase-conjugated goat anti-rabbit IgG (Jackson ImmunoResearch Laboratories; West Grove, PA, USA) at a 1:2,000 dilution for 2 hours at room temperature and washed three times with TBST. As a loading control, the same membranes were stripped and probed with monoclonal anti-α-tubulin (Sigma) at a 1:3,000 dilution at 4 °C overnight, followed by an incubation with the goat anti-mouse IgG used above at a 1:3,000 dilution for 1 hour at room temperature and three washes with TBST. Immunoreactive proteins were visualized with WEST-ONE TM chemiluminescent substrate (iNtRON Biotechnology) and signals were detected with LAS-3000 (FujiFilm, Tokyo, JAPAN).

6. Mice and Housing

All animal experiments were approved by the Institutional Animal Care and Use Committee (IACUC), and performed at the Clinical Research Institute, Seoul National University Hospital, Seoul, Korea (an AAALAC accredited facility). National Research Council (NRC) guidelines for the care and use of laboratory animals were observed at all times. The mice were bred and housed under pathogen-free conditions with controlled humidity (30%-50%) and temperature (21-24 °C). A light program regulated a 12/12-h light dark-rhythm, with lights on from 8 a.m. to 8 p.m. The mice were kept in Macrolon® cages on sawdust bedding (Sniff 3/4; Altrogge; Lage, Germany). Standard mouse diet (Altromin 1326; Altrogge) and filtered city tap water from standard Perspex drinking bottles were provided ad libitum. Male Balb/c mice (6 weeks old; 25-30 g) were implanted with an EGFR-positive mouse breast sarcoma cell line (EMT-6), as described below.

7. Mouse Tumor Models and Measurement of Tumor Growth Delay

Animals were injected subcutaneously in the right thigh with 1x106 tumor cells in a saline suspension volume of 50 μl. One tumor per animal was implanted. Mice with an average tumor volume of 200-300 mm3 were grouped as follows: Vehicle only = vehicle (100 μl) for 7 consecutive days, three times a day; “Vehicle+RT(10Gy)” = irradiation with 10 Gy followed by vehicle (100 μl) for 7 consecutive days, three times a day; “Vehicle+RT(20Gy)” = irradiation with 20 Gy, followed by vehicle (100 μl) for 7 consecutive days, three times a day; EGF only = rhEGF 1.0 mg/kg for 7 consecutive days, three times a day; “EGF+RT(10Gy)” = irradiation with 10 Gy, followed by rhEGF (1.0 mg/kg) for 7 consecutive days, three times a day; “EGF+RT(20Gy)” = irradiation with 20 Gy followed by rhEGF (1.0 mg/kg) for 7 consecutive days, three times a day. rhEGF and vehicle was given intraperitoneally at 8 am, 1 pm, and before RT.

Each group consisted of five to seven animals. Mice were irradiated in a custom-maid mouse thigh jig with 4 MV X-rays generated by a linear accelerator (Clinac 4/100) at a dose rate of 250 MU/min. Length and width of the tumors (in mm) were measured with digital calipers three times a week by two independent researchers (KEK and LSH) for 21 days after irradiation, or until the tumor volume reached five times (5x) the original pretreatment volume. These measurement was performed by researcher unaware of treatments. Tumor volume (mm3) was calculated according to the following formula: tumor volume = 1/2 x length x width x width. The data are expressed as the relative tumor volume ± standard deviation (SD), which is the ratio of the tumor volume measured each day to the pretreatment volume in each experimental condition. Experiments were independently repeated three times.

8. Statistical Analysis

All values are presented as means ± standard deviation (SD), and n indicates the number of observations (in vitro) or the number of animals in the treatment group (in vivo). In vivo, the relative differences in tumor growth in EMT-6-implanted mice treated with rhEGF only, irradiation only, or both were analyzed by analysis of variance and expressed as p values. A p value of less than 0.05 was considered to be significant. Three independent experiments performed on different days were used for statistical analysis.

RESULTS

1. Expression of EGFR in Normal Fibroblasts and Cancer Cell Lines

To figure out difference in functional consequences according to the expression level of EGFR, western blot analysis was performed for various cell lines including NCI-H460, NCI-H1299, A549, HeLa, EMT-6, AMC-HN9, AMC-HN3, human cervix fibroblasts, and F65 human skin fibroblasts. We confirmed different level of EGFR protein expression among these cell lines (Fig. 1). For subsequent experiments, we selected three cancer cell lines with different expression level of EGFR: highly expressed, AMC-HN3; intermediate, A549; lowly expressed, EMT-6, respectively.

Fig. (1)

Expression of epidermal growth factor receptor in various cancer cell lines and normal fibroblasts.



We repeated the proliferation experiments using another rhEGF purchased from R&D Systems Inc. (Minneapolis, MN, USA) and confirmed that there was no difference in rhEGF effects according to the manufacturers (data not shown).

2. Effect of rhEGF on Proliferation in Normal Fibroblasts and Cancer Cell Lines

Three cancer cell lines, AMC-HN3, A549, and EMT-6, were cultured with varying concentrations of rhEGF (0.01-1000nM) for five days, and clonogenic assays were performed. For AMC-HN3 cell lines, the number of colonies was decreased in a dose-dependent manner. The number of colonies of A549 and EMT-6 cell lines was also decreased by the concentrations above 0.1 nM (Fig. 2) and we observed similar effects under serum-free conditions (data not shown).

Fig. (2)

Results of clonogenic assays of rhEGF-treated cells.

(a) AMC-HN3, (b) A549, (c) EMT-6, (d) normal cervix fibroblast.

The cells were incubated for 24 hours prior to treatment with 0, 0.01, 0.1, 1, 10, 100, or 1000 nM rhEGF. After 10 days of incubation at 37 °C, colonies were counted. In the AMC-HN3 cells, the number of colonies decreased as the rhEGF concentration increased. In contrast, rhEGF increased the number of colonies formed from normal fibroblasts.



We treated primary human fibroblasts cultured from a normal uterine cervix sample with various concentrations of rhEGF, ranging from 0.01 to 1000 nM. rhEGF treatment increased the number of colonies (Fig. 2). We also observed similar effects under serum-free conditions (data not shown).

3. The Effect of rhEGF on Cell Killing by Ionizing Radiation

We subjected our three cancer cell lines and normal fibroblasts to ionizing radiation, followed by a ten-day culture with unsupplemented medium or medium containing 10nM of rhEGF. In the clonogenic assays, we observed that rhEGF had a radio-sensitizing effect on AMC-HN3 cells, but it had no significant effect in A549 and EMT-6 cell lines. In normal fibroblasts, rhEGF inhibited the cell killing effect of radiation (Fig. 3).

Fig. (3)

Effects of rhEGF on cell killing of ionizing radiation.

(a) AMC-HN3, (b) A549, (c) EMT-6, (d) normal cervix fibroblast.

Cells were simultaneously irradiated and treated with rhEGF (10nM). After 24 hours, the medium was removed, and cells were incubated in drug-free media for 10 days to form colonies. rhEGF radiosensitized AMC-HN3 cells, but protected normal fibroblasts from the killing effect of radiation.



4. Changes in Expression Levels of PCNA and Ki-67 in Normal Fibroblasts and Cancer Cell Lines Treated with rhEGF

After culturing serum-starved cells with 10 nM rhEGF for varying time periods (5 min, 4 hr, 24 hr, 48 hr, and 72 hr), we measured expression levels of two proliferation-associated proteins, PCNA and Ki67, using immunoblotting. We detected both proteins in all cell lines, even under control (no rhEGF) conditions. Treatment with rhEGF significantly decreased Ki67 levels in all three cancer cell lines (AMC-HN3, A549, and EMT-6). Ki67 was hardly expressed in three cancer cell lines at 72 hr. In contrast, rhEGF substantially enhanced Ki67 expression in normal fibroblasts (Fig. 4).

Fig. (4)

rhEGF-induced changes in expression of EGFR, Ki67, and PCNA with respect to time.

The cells were incubated for 18-24 hours in serum-free media (0.5% FBS) and treated with rhEGF (10nM) for 5 min, 4, 24, 48, or 72 hours. Ki67 significantly decreased in cancer cell lines and increased in the normal fibroblasts.



5. Effect of rhEGF on Tumor Growth Delay of Ionizing Radiation in Animal Tumor Model

To ascertain whether rhEGF effects in vitro translated into tumor growth delay in vivo, we implanted Balb/c mice with EMT-6 cancer cells via subcutaneous injection and monitored tumor volumes following radiotherapy, rhEGF treatment, or both. After 21 days, the relative tumor volume was 8.0 in the control (vehicle only) group (Fig. 5). A single radiation dose of 10 Gy or 20 Gy significantly delayed tumor growth; relative tumor volumes were 4.6 (p < 0.001) and 3.0 (p < 0.001) mm3, in these respective groups. Interestingly, rhEGF treatment alone also delayed tumor growth; this group displayed a relative tumor volume of 6.0 (p < 0.001). Relative tumor volumes between the group that received radiation plus rhEGF and the group that received radiation alone were not statistically different. Importantly, these results verify that rhEGF did not stimulate tumor growth under these conditions.

Fig. (5)

Effects of rhEGF on tumor growth delay of ionizing radiation in Balb/c mice implanted with EMT-6 cells.

Each group was irradiated (if indicated) and then treated as indicated for 7 consecutive days, three times a day, following the irradiation. Vehicle only = vehicle (100μl) without irradiation; Vehicle+IR(10Gy) = vehicle (100μl) with 10 Gy; Vehicle+IR(20Gy) = vehicle (100μl) with 20 Gy; EGF only = EGF (1.0 mg/kg) without irradiation; EGF+IR(10Gy) = EGF (1.0 mg/kg) with 10 Gy; EGF+IR(20Gy) = EGF (1.0 mg/kg) with 20 Gy. The data are means ± SD of three independent experiments. rhEGF, whether given alone or combined with radiation, did not stimulate tumor growth.



DISCUSSION

In this study, rhEGF enhanced the proliferation of normal fibroblasts, and inhibited the cell killing effect of radiation in this cell line. In contrast, AMC-HN3 cells showed significantly increased cell death upon rhEGF treatment, although there was no significant effect on A549 and EMT-6 cells lines. In the animal tumor model using EMT-6 cells, rhEGF treatment did not inhibit the cell killing effect of radiation.

In addition, we showed rhEGF increased the expression of Ki67, which is a 359-kD nuclear protein expressed by proliferating cells in all phases of the active cell cycle. On the other hand, PCNA showed relatively little change in its expression compared to Ki67. PCNA is a 36-kD non-histone nuclear protein that plays a fundamental role in initiating cell proliferation, and it is also a marker for cells in early G1 or S phases of the cell cycle. The lack of an effect on PCNA expression suggests that rhEGF might affect cells during G2 or M phases of the cell cycle. Still, the mechanisms of the differential effect of rhEGF on various cancer cell lines are unknown. In the previous work, high concentrations of EGF (nanomolar level) inhibited growth and promoted apoptosis of the human epidermoid carcinoma cell line A431 [19,20]. The A431 cells, like AMC-HN3 cells, also express high levels of EGFR. However, the interaction among EGF, EGFR, and radiation is a complex issue that needs thorough approach, and this issue is beyond the scope of our study. Further studies are needed to confirm the efficacy of rhEGF in a wider variety of cancer cell lines as well as to elucidate the mechanisms of such observation.

The most important finding of the present study is that rhEGF treatment did not inhibit the cell killing effect of ionizing radiation on cancer cell lines, both in vitro and in vivo. As mentioned earlier, rhEGF was already shown to be effective for the recovery of radiation-induced mucosal damage in the animal models [9,10]. Taken together, our study may support the hypothesis that rhEGF can be used as a safe and effective radioprotector.

However, there are several concerns that should to be clarified for the clinical application of rhEGF at the present time. First, our in vivo model was based on the murine mammary tumor with relatively low expression of EGFR. Although the higher expression level of EGFR was associated with increased cell death and even radiosensitization upon rhEGF treatment, it is not certain whether similar observation would be repeated in the in vivo model using human cancer cell lines with high expression of EGFR. Second, the fractionation scheme utilized in the current study is different from the conventional fractionation in the clinical setting. Lastly, 10 nM dose of rhEGF was based on the study conducted by Gulli et al. [21], but it is still unknown whether this is the optimal concentration and whether the dose-response relationship exist.

In conclusion, results of our study demonstrated that rhEGF effectively stimulated proliferation and radiation recovery in normal fibroblasts without promoting the growth of tumor cells. Therefore, it may be clinically valuable in preventing and/or treating radiation-induced tissue injuries and it may also potentially increase the therapeutic index of radiotherapy.

ACKNOWLEDGEMENTS

This work was supported by grant No. 0620270 from the National R&D Program for Cancer Control, Ministry of Health Family & Welfare, Republic of Korea, and grant No. R01-2008-000-20581-0 from the Korea Science and Engineering Foundation grant funded by the Korea government (MEST).

REFERENCES

Track Your Manuscript:


Endorsements



"Open access will revolutionize 21st century knowledge work and accelerate the diffusion of ideas and evidence that support just in time learning and the evolution of thinking in a number of disciplines."


Daniel Pesut
(Indiana University School of Nursing, USA)

"It is important that students and researchers from all over the world can have easy access to relevant, high-standard and timely scientific information. This is exactly what Open Access Journals provide and this is the reason why I support this endeavor."


Jacques Descotes
(Centre Antipoison-Centre de Pharmacovigilance, France)

"Publishing research articles is the key for future scientific progress. Open Access publishing is therefore of utmost importance for wider dissemination of information, and will help serving the best interest of the scientific community."


Patrice Talaga
(UCB S.A., Belgium)

"Open access journals are a novel concept in the medical literature. They offer accessible information to a wide variety of individuals, including physicians, medical students, clinical investigators, and the general public. They are an outstanding source of medical and scientific information."


Jeffrey M. Weinberg
(St. Luke's-Roosevelt Hospital Center, USA)

"Open access journals are extremely useful for graduate students, investigators and all other interested persons to read important scientific articles and subscribe scientific journals. Indeed, the research articles span a wide range of area and of high quality. This is specially a must for researchers belonging to institutions with limited library facility and funding to subscribe scientific journals."


Debomoy K. Lahiri
(Indiana University School of Medicine, USA)

"Open access journals represent a major break-through in publishing. They provide easy access to the latest research on a wide variety of issues. Relevant and timely articles are made available in a fraction of the time taken by more conventional publishers. Articles are of uniformly high quality and written by the world's leading authorities."


Robert Looney
(Naval Postgraduate School, USA)

"Open access journals have transformed the way scientific data is published and disseminated: particularly, whilst ensuring a high quality standard and transparency in the editorial process, they have increased the access to the scientific literature by those researchers that have limited library support or that are working on small budgets."


Richard Reithinger
(Westat, USA)

"Not only do open access journals greatly improve the access to high quality information for scientists in the developing world, it also provides extra exposure for our papers."


J. Ferwerda
(University of Oxford, UK)

"Open Access 'Chemistry' Journals allow the dissemination of knowledge at your finger tips without paying for the scientific content."


Sean L. Kitson
(Almac Sciences, Northern Ireland)

"In principle, all scientific journals should have open access, as should be science itself. Open access journals are very helpful for students, researchers and the general public including people from institutions which do not have library or cannot afford to subscribe scientific journals. The articles are high standard and cover a wide area."


Hubert Wolterbeek
(Delft University of Technology, The Netherlands)

"The widest possible diffusion of information is critical for the advancement of science. In this perspective, open access journals are instrumental in fostering researches and achievements."


Alessandro Laviano
(Sapienza - University of Rome, Italy)

"Open access journals are very useful for all scientists as they can have quick information in the different fields of science."


Philippe Hernigou
(Paris University, France)

"There are many scientists who can not afford the rather expensive subscriptions to scientific journals. Open access journals offer a good alternative for free access to good quality scientific information."


Fidel Toldrá
(Instituto de Agroquimica y Tecnologia de Alimentos, Spain)

"Open access journals have become a fundamental tool for students, researchers, patients and the general public. Many people from institutions which do not have library or cannot afford to subscribe scientific journals benefit of them on a daily basis. The articles are among the best and cover most scientific areas."


M. Bendandi
(University Clinic of Navarre, Spain)

"These journals provide researchers with a platform for rapid, open access scientific communication. The articles are of high quality and broad scope."


Peter Chiba
(University of Vienna, Austria)

"Open access journals are probably one of the most important contributions to promote and diffuse science worldwide."


Jaime Sampaio
(University of Trás-os-Montes e Alto Douro, Portugal)

"Open access journals make up a new and rather revolutionary way to scientific publication. This option opens several quite interesting possibilities to disseminate openly and freely new knowledge and even to facilitate interpersonal communication among scientists."


Eduardo A. Castro
(INIFTA, Argentina)

"Open access journals are freely available online throughout the world, for you to read, download, copy, distribute, and use. The articles published in the open access journals are high quality and cover a wide range of fields."


Kenji Hashimoto
(Chiba University, Japan)

"Open Access journals offer an innovative and efficient way of publication for academics and professionals in a wide range of disciplines. The papers published are of high quality after rigorous peer review and they are Indexed in: major international databases. I read Open Access journals to keep abreast of the recent development in my field of study."


Daniel Shek
(Chinese University of Hong Kong, Hong Kong)

"It is a modern trend for publishers to establish open access journals. Researchers, faculty members, and students will be greatly benefited by the new journals of Bentham Science Publishers Ltd. in this category."


Jih Ru Hwu
(National Central University, Taiwan)


Browse Contents




Webmaster Contact: info@benthamopen.net
Copyright © 2021 Bentham Open